Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

Detailed price information for Castle Biosciences Inc (CSTL-Q) from The Globe and Mail including charting and trades.

Stantec reports strong third quarter 2025 results, delivering over 17% growth in adjusted earnings per share

Highlights Net revenue of $1.7 billion, an increase of 11.8% compared to Q3 2024Adjusted EBITDA1 increase of 17.8% to $323.4 million and adjusted EBITDA margin1 of 19.0%, a 100 basis point increase ...
The Malaysian Reserve

Edgewell Personal Care Announces Fourth Quarter and Fiscal 2025 Results; Provides 2026 Outlook

Fourth Quarter Net Sales increased 3.8%, or 2.5% Organic increase Fiscal 2025 Net Sales decreased 1.3%, or 1.3% Organic decrease Fiscal 2025 GAAP EPS ...

Xos Extends Profitability Streak with Strong Q3 2025 Performance and Positive Operating Cash Flow

Delivered 130 units and generated $16.5 million in revenueAchieved 15.3% Gross Margin and a second consecutive quarter of positive free cash flow ...